1
David M Goldenberg: Immunotherapy of B-cell malignancies using anti-CD22 antibodies. Immunomedics, Foley & Lardner, October 23, 2001: US06306393 (244 worldwide citation)

B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, includin ...


2
David M Goldenberg: Immunotherapy of B-cell malignancies using anti-CD22 antibodies. Immunomedics, Foley & Lardner, February 6, 2001: US06183744 (137 worldwide citation)

B-Cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, includin ...


3
David M Goldenberg: Immunotherapy of B-cell malignancies using anti-CD22 antibodies. Immunomedics, Rossi Kimms & McDowell, January 31, 2012: US08105596 (36 worldwide citation)

B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including che ...


4
David M Goldenberg: Immunotherapy of B-cell malignancies using anti-CD22 antibodies. Immunomedics, Rossi Kimms & McDowell, March 22, 2011: US07910103 (27 worldwide citation)

B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including che ...


5
David M Goldenberg: Immunotherapy of B-cell malignancies using anti-CD22 antibodies. Immunomedics, Rossi Kimms & McDowell, November 23, 2010: US07837995 (10 worldwide citation)

B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including che ...


6
David M Goldenberg: Immunotherapy of B-cell malignancies using anti-CD22 antibodies. Immunomedics, Rossi Kimms & McDowell, May 10, 2011: US07939073 (6 worldwide citation)

B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including che ...


7
Goldenberg David M: Immunotherapy of b-cell malignancies using anti-cd22 antibodies. Immunomedics, February 13, 2002: EP1178826-A1 (2 worldwide citation)

B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including che ...


8
Goldenberg David M: Immunotherapy of b-cell malignancies using anti-cd22 antibodies. Immunomedics, January 12, 2000: EP0969866-A1 (2 worldwide citation)

B-Cell malignacies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chem ...


9
Goldenberg David M: Immunotherapy of b-cell malignancies using anti-cd22 antibodies. Immunomedics, Goldenberg David M, SAXE Bernhard D, October 1, 1998: WO/1998/042378 (1 worldwide citation)

B-Cell malignacies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chem ...


10
Goldenberg David M: Immunotherapy of b-cell malignancies using anti-cd22 antibodies. Immunomedics, September 22, 2004: EP1459768-A2

B-Cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including che ...